Table 2.
Clinical and immunohistochemical findings of 10 cases of gastric-type endocervical adenocarcinoma
| Case No. | Age (yr) | Preparation type | Cytologic diagnosis | Type of surgery | FIGO stage | HPV | p16 | p53 | MUC-6 | Adjuvant treatment | Follow-up (mo) | Outcome | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||
| CS | LBP | ||||||||||||
| 1 | 48 | + | + | AIS | Trachelectomy | IVA | − | − | + | + | CC | 20 | DOD |
| 2 | 80 | + | + | Adenocarcinoma | RH | IIB | − | − | Wild | −a | RT | 38 | DOD |
| 3 | 52 | + | + | AGC | RH | IIIC1 | − | − | Wild | + | CCRT | 48 | AWD |
| 4 | 58 | + | + | Adenocarcinoma | RH | IVA | −b | − | + | + | CC | 23 | DOD |
| 5 | 54 | + | + | Adenocarcinoma | RH | IIA1 | − | + | + | + | NA | FU loss | NA |
| 6 | 54 | NA | NA | NA | Conization | IIIC1 | − | − | Wild | + | CCRT | 17 | DOD |
| 7 | 78 | NA | + | Adenocarcinoma | Conization | IIA2 | − | − | + | −a | RT | 21 | NED |
| 8 | 63 | NA | + | AGC | RH | IB1 | − | − | Null | + | CCRT | 21 | NED |
| 9 | 76 | NA | + | AGC | RH | IIB | − | − | + | + | RT | 10 | AWD |
| 10 | 54 | NA | NA | NA | RH | IIIC1 | − | − | Wild | + | CCRT | 10 | AWD |
CS, conventional smear; LBP, liquid-based preparation; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomavirus; AIS, adenocarcinoma in situ; CC, combined chemotherapy; DOD, died of disease; RH, radical hysterectomy; RT, radiotherapy; AGC, atypical glandular cells, favor neoplastic; CCRT, combined chemotherapy and radiotherapy; AWD, alive with disease; NA, not available; FU, follow-up; NED, no evidence of disease.
a
Pale pinkish-red cytoplasmic neutral mucin on Alcian blue/PAS special staining;
b
High risk HPV DNA in situ hybridization; +, p16, block-type positivity; +, p53, overexpression.